Aldeyra Therapeutics, Inc. (ALDX) intrinsic value & 10-year financials
Aldeyra Therapeutics, Inc. (ALDX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.70
- Market cap
- $42.0M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- -280.2%
- Free cash flow (FY2025)
- —
ALDX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$33.8M | -$0.56 | — | — | -336.4% |
| FY2024 | — | -$55.9M | -$0.94 | — | — | -503.1% |
| FY2023 | — | -$37.5M | -$0.64 | — | — | -577.8% |
| FY2022 | — | -$62.0M | -$1.06 | -$56.7M | — | -895.6% |
| FY2021 | — | -$57.8M | -$1.07 | -$42.6M | — | 732.9% |
| FY2020 | — | -$37.6M | — | — | — | -638.2% |
| FY2019 | — | -$60.8M | — | -$45.0M | — | -168.0% |
| FY2018 | — | -$38.9M | — | -$30.1M | — | -104.2% |
| FY2017 | — | -$22.3M | — | -$19.2M | — | -141.1% |
| FY2016 | — | -$18.7M | — | -$15.2M | — | -170.7% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Aldeyra Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Aldeyra Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -27.1% ROIC.
Aldeyra Therapeutics, Inc. has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Aldeyra Therapeutics, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.